Corneal Cross‑linking (CXL) Procedure
Customize your policy alerts
Sign up for all husky_health policy alerts
Know when husky_health releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity, prior authorization requirements, coverage criteria, and documentation needed for corneal cross-linking (CXL) for members of the HUSKY Health (Connecticut Medicaid) program.
No material clinical or coverage changes in this revision.
Coverage Criteria for Corneal Cross-Linking (CXL)
Medical necessity criteria
Photochemical corneal cross-linking (CXL) may be considered medically necessary when ALL of the following are met:
Main medical necessity conditions
- Accepted diagnoses: Progressive and/or unstable Keratoconus OR Corneal ectasia following refractive surgery
- Contraindications absent: No prior herpetic ocular infection AND no history of corneal disease or injury (e.g., chemical injury, delayed epithelial healing)
- Procedure-specific criteria: Epi-off: age ≥14 AND provider attests corneal thickness will be increased to ≥400 microns during the procedure; OR Epi-on: age ≥13 AND provider attests corneal thickness will be increased to ≥325 microns during the procedure
Provider attestation of intra-procedural corneal thickness is required on the authorization request
Use of corneal cross-linking (CXL) outside the indications listed in this policy — including but not limited to treatment of infectious keratitis and CXL performed in combination with other ocular procedures (for example, intrastromal corneal ring segments, photorefractive keratectomy [PRK], or phakic intra‑ocular lens implantation) — is not routinely authorized. Such requests will be evaluated on a case‑by‑case basis with clinical documentation submitted to support medical necessity for the specific circumstance.
Indications for CXL that fall outside the diagnoses and the criteria enumerated in this policy are not covered by default and are subject to review. Providers should submit a prior authorization request with complete clinical documentation for any indication not explicitly listed; coverage determinations will be made based on the submitted case‑specific information.
Coding and Procedure Identifiers
| 66999 | Unlisted procedure, anterior segment of eye |
Provider Actions, Prior Authorization, and Documentation
Prior authorization required for CXL
Prior authorization is required for corneal cross-linking (CXL). Requests will be reviewed as surgical procedures and coverage determinations are based on submitted case-specific information.
Provider responsibilities and alerts
Ensure prior authorization is obtained and submit complete case-specific information; failure to provide necessary details may affect coverage decisions.
- Confirm diagnosis meets medical necessity criteria (progressive/unstable keratoconus or post-refractive surgery ectasia).
- Verify absence of contraindications (e.g., prior herpetic ocular infection, history of corneal disease or injury).
- Confirm procedure-specific age and corneal thickness criteria are met and attested on the request.
Required prior authorization documentation
Submit a fully completed Corneal Cross-linking (CXL) Procedure Prior Authorization Request Form along with documentation from the requesting provider supporting medical necessity and any other information requested by CHNCT.
Provider attestation of corneal thickness and age
On the authorization request the provider must attest that corneal thickness will be increased to the policy-specified minimum during the procedure: ≥400 μm for epi-off and ≥325 μm for epi-on, and confirm applicable patient age criteria.
- Epi-off: attest corneal thickness will be increased to at least 400 microns and patient age ≥14.
- Epi-on: attest corneal thickness will be increased to at least 325 microns and patient age ≥13.
Denial risk if prior authorization is not obtained
Lack of prior authorization for the CXL procedure may result in denial of coverage or payment.
Background
Corneal cross‑linking (CXL) is a minimally invasive photochemical procedure that uses riboflavin (vitamin B2) applied to the cornea and activation with ultraviolet (UV) light to create additional covalent bonds within corneal collagen. The intended clinical effect is to strengthen the corneal stroma and slow or arrest progression of ectatic disorders such as keratoconus and corneal ectasia following refractive surgery. Two common approaches are described: epi‑off, in which the central corneal epithelium is removed prior to riboflavin instillation, and epi‑on (transepithelial), in which the epithelium is left intact.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.